Literature DB >> 30118159

Differences between patient- and proxy-reported HRQoL using the Wound-QoL.

Rachel Sommer1, Carsten Hampel-Kalthoff2, Brigitte Kalthoff2, Christopher Neht1, Erwin Scherfer2, Manfred Winkler2, Christine Blome1.   

Abstract

The purpose of this study was to examine the patient- and proxy-report agreement on the Wound-quality of life (QoL) questionnaire to assess health-related QoL in patients with chronic wounds. Patients and their proxies (in this case, relatives) were recruited via different nursing services in Germany and asked to complete the Wound-QoL. Intraclass correlation coefficients were calculated for each Wound-QoL scale and the total score, and weighted Cohen's Kappa coefficients for individual items. Proxies tended to report lower health-related QoL in the Wound-QoL than their relatives with chronic wounds. Agreement between the two perspectives was moderate on single-item level and excellent on scale level. Proxy-reports can be helpful, if patients are unable to provide information, although caution remains when interpreting the results. However, the patient's own perspective remains preferable.
© 2018 by the Wound Healing Society.

Entities:  

Mesh:

Year:  2018        PMID: 30118159     DOI: 10.1111/wrr.12662

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  2 in total

Review 1.  A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia.

Authors:  Philip Goodney; Samir Shah; Yiyuan David Hu; Bjoern Suckow; Scott Kinlay; David G Armstrong; Patrick Geraghty; Megan Patterson; Matthew Menard; Manesh R Patel; Michael S Conte
Journal:  J Vasc Surg       Date:  2022-01-24       Impact factor: 4.860

2.  Determining the Minimal Important Difference for the Wound-QoL Questionnaire.

Authors:  Janine Topp; Christine Blome; Matthias Augustin; Nicole Mohr; Eike Sebastian Debus; Holger Diener; Rachel Sommer
Journal:  Patient Prefer Adherence       Date:  2021-07-14       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.